Status:
COMPLETED
Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature
Lead Sponsor:
Pfizer
Conditions:
Idiopathic Short Stature
Eligibility:
All Genders
3-10 years
Phase:
PHASE3
Brief Summary
To demonstrate that an individualized, formula-based Genotropin regimen for children with Idiopathic Short Stature will lead to a targeted height gain (to reach the target of 10th percentile (%), or -...
Eligibility Criteria
Inclusion
- Prepubertal children with bone ages between 3 and 10 years of age for males and 3 and 9 years of age for females
- Naive to Growth Hormone treatment
Exclusion
- Abnormal karyotype. Small Gestational Age and Skeletal dysplasia.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
316 Patients enrolled
Trial Details
Trial ID
NCT00396097
Start Date
December 1 2006
End Date
August 1 2012
Last Update
April 5 2016
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Arkansas Children's Hospital
Little Rock, Alaska, United States, 72202
2
Arkansas Children's Hospital
Little Rock, Arkansas, United States, 72202
3
Children's Hospital of Los Angeles
Los Angeles, California, United States, 90027
4
Rady Children's Hospital - San Diego
San Diego, California, United States, 32123-4282